APA (7th ed.) Citation

L, E., N, J., S, P., W, C., M, A., S, S., . . . A, N. (2023). Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Therapeutic advances in medical oncology, 15, 17588359231156392. https://doi.org/10.1177/17588359231156392

Chicago Style (17th ed.) Citation

L, Emmett, et al. "Patient Outcomes Following a Response Biomarker-guided Approach to Treatment Using 177Lu-PSMA-I&T in Men with Metastatic Castrate-resistant Prostate Cancer (Re-SPECT)." Therapeutic Advances in Medical Oncology 15 (2023): 17588359231156392. https://doi.org/10.1177/17588359231156392.

MLA (9th ed.) Citation

L, Emmett, et al. "Patient Outcomes Following a Response Biomarker-guided Approach to Treatment Using 177Lu-PSMA-I&T in Men with Metastatic Castrate-resistant Prostate Cancer (Re-SPECT)." Therapeutic Advances in Medical Oncology, vol. 15, 2023, p. 17588359231156392, https://doi.org/10.1177/17588359231156392.